blank Aide rapide
blank Actualité maintenance

Dates prévues pour la maintenance

Interruptions régulières:
entre 5 h 00 et 5 h 15 HEC, du lundi au dimanche.

Autres interruptions
Accessibilité

2022.02.11

en savoir plus...
blank Flash info

Flash Info

Nouvelle version du Registre européen des brevets – des informations relatives aux procédures CCP sont disponibles dans le Registre européen des brevets.

2024-07-24

en savoir plus...
blank Liens utiles

Notifications
Assistant du Registre européen des brevets
Manuel d’utilisation du Registre européen des brevets
Registre européen des brevets – guide de poche
FAQ - Registre européen des brevets
Registre fédéré (Flyer)
Dossier mondial (Flyer)
Événements du Registre
Couverture de données pour lien profonds
Contenue du Registre fédéré
Tour de l'information brevets
Charte d'utilisation équitable

Extrait du Registre européen des brevets

EP Présentation générale: EP2638044

EP2638044 - 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES À SUBSTITUTION ALCOXY [Cliquez sur ce lien avec le bouton droit de la souris pour le conserver dans vos signets]
StatutAucune opposition formée dans le délai
Statut actualisé le  06.07.2018
Base de données mise à jour au 29.10.2024
PrécédentLe brevet a été délivré
Statut actualisé le  28.07.2017
PrécédentLa délivrance du brevet est envisagée
Statut actualisé le  04.04.2017
PrécédentL'examen est en cours
Statut actualisé le  03.01.2017
Dernier événement   Tooltip17.07.2020Extinction du brevet dans un Etat contractant
Nouvel/nouveaux État(s): AL		publié le 19.08.2020  [2020/34]
Demandeur(s)Pour tous les Etats désignés
Bayer Intellectual Property GmbH
Alfred-Nobel-Strasse 10
40789 Monheim / DE
[2017/18]
Précédent [2013/38]Pour tous les Etats désignés
Bayer Pharma Aktiengesellschaft
Müllerstrasse 178
13353 Berlin / DE
Inventeur(s)01 / SCOTT, William, Johnston
210 Saddle Hill Drive
Guilford 06437 / US
02 / MÖWES, Manfred
Massmannstr. 9
12163 Berlin / DE
03 / BÖMER, Ulf
Leipziger Str. 49
16548 Glienicke / DE
04 / MÖNNING, Ursula
Eichendamm 5
15569 Woltersdorf / DE
05 / LIU, Ningshu
Ringstrasse 89a
12203 Berlin / DE
 [2013/38]
Mandataire(s)BIP Patents
c/o Bayer Intellectual Property GmbH
Alfred-Nobel-Straße 50
40789 Monheim am Rhein / DE
[N/P]
Précédent [2017/35]BIP Patents
c/o Bayer Intellectual Property GmbH
Alfred-Nobel-Straße 10
40789 Monheim am Rhein / DE
Précédent [2013/38]BIP Patents
c/o Bayer Intellectual Property GmbH
Creative Campus Monheim
Alfred-Nobel-Straße 10
40789 Monheim / DE
Numéro de la demande, date de dépôt11784977.808.11.2011
[2017/35]
WO2011EP69634
Numéro de priorité, dateUS20100412508P11.11.2010         Format original publié: US 412508 P
[2013/38]
Langue de dépôtEN
Langue de la procédureEN
PublicationType: A1 Demande avec rapport de recherche
N°:WO2012062745
Date:18.05.2012
Langue:EN
[2012/20]
Type: A1 Demande avec rapport de recherche 
N°:EP2638044
Date:18.09.2013
Langue:EN
La demande publiée par l'OMPI le 18.05.2012, dans une des langues officielles de l'OEB, remplace la publication de la demande de brevet européen.
[2013/38]
Type: B1 Fascicule de brevet 
N°:EP2638044
Date:30.08.2017
Langue:EN
[2017/35]
Rapport(s) de rechercheRapport de recherche internationale - publié le:EP18.05.2012
ClassificationIPC:C07D487/04, A61P35/02, A61P35/04, A61K31/519
[2017/15]
CPC:
C07D487/04 (EP,US); A61K31/541 (US); A61K31/519 (US);
A61K31/5377 (US); A61K39/39558 (US); A61P29/00 (EP);
A61P35/00 (EP); A61P35/02 (EP); A61P35/04 (EP);
A61P37/00 (EP); A61P43/00 (EP) (-)
Précédent IPC [2013/38]C07D487/04
Etats contractants désignésAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/38]
Etats autorisant lextensionBAPas encore payé
MEPas encore payé
TitreAllemand:ALKOXYSUBSTITUIERTE 2,3-DIHYDROIMIDAZO[1,2-C]CHINAZOLINE[2013/38]
Anglais:ALKOXY-SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES[2013/38]
Français:2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES À SUBSTITUTION ALCOXY[2013/38]
Entrée dans la phase régionale11.06.2013Taxe nationale de base payée 
11.06.2013Taxe(s) de désignation payée(s) 
11.06.2013Taxe d'examen payée 
Procédure d'examen11.06.2013Requête en examen déposée  [2013/38]
30.12.2013Modification par le demandeur (revendications et/ou déscription)
02.05.2014Envoi d'une notification de la division d'examen (délai : M06)
04.11.2014Réponse à une notification de la division dexamen
18.02.2015Envoi d'une notification de la division d'examen (délai : M06)
28.08.2015Réponse à une notification de la division dexamen
22.06.2016Envoi d'une notification de la division d'examen (délai : M06)
29.12.2016Réponse à une notification de la division dexamen
05.04.2017Notification relative à l'intention de délivrer le brevet
17.07.2017Taxe de délivrance payée
17.07.2017Taxe publication/d‘impression payée
17.07.2017Réception des traductions de la/des revendication(s)
Demande(s) divisionnaire(s)La date de la première notification de la division d'examen relative à la demande la plus ancienne pour laquelle une notification a été émise est  02.05.2014
Opposition(s)31.05.2018Aucune opposition formée dans le délai imparti [2018/32]
Taxes payéesTaxe annuelle
18.11.2013Taxe annuelle Année du brevet 03
10.11.2014Taxe annuelle Année du brevet 04
10.11.2015Taxe annuelle Année du brevet 05
10.11.2016Taxe annuelle Année du brevet 06
Dérogation à la compétence  Tooltip
exclusive de la juridiction
unifiée du brevet		 Voir le Registre de la juridiction unifiée du brevet pour les données relatives à la dérogation
La juridiction unifiée du brevet assume l'entière responsabilité de l'exactitude, de l'exhaustivité et de la qualité des données présentées sous le lien fourni.
Extinctions durant la phase d’opposition  TooltipHU08.11.2011
AL30.08.2017
AT30.08.2017
CY30.08.2017
CZ30.08.2017
DK30.08.2017
EE30.08.2017
FI30.08.2017
HR30.08.2017
LT30.08.2017
LV30.08.2017
MC30.08.2017
MK30.08.2017
NL30.08.2017
PL30.08.2017
PT30.08.2017
RO30.08.2017
RS30.08.2017
SE30.08.2017
SI30.08.2017
SK30.08.2017
SM30.08.2017
TR30.08.2017
IE08.11.2017
LU08.11.2017
MT08.11.2017
BE30.11.2017
BG30.11.2017
CH30.11.2017
LI30.11.2017
NO30.11.2017
GR01.12.2017
IS30.12.2017
[2020/34]
Précédent [2020/27]HU08.11.2011
AT30.08.2017
CY30.08.2017
CZ30.08.2017
DK30.08.2017
EE30.08.2017
FI30.08.2017
HR30.08.2017
LT30.08.2017
LV30.08.2017
MC30.08.2017
MK30.08.2017
NL30.08.2017
PL30.08.2017
PT30.08.2017
RO30.08.2017
RS30.08.2017
SE30.08.2017
SI30.08.2017
SK30.08.2017
SM30.08.2017
TR30.08.2017
IE08.11.2017
LU08.11.2017
MT08.11.2017
BE30.11.2017
BG30.11.2017
CH30.11.2017
LI30.11.2017
NO30.11.2017
GR01.12.2017
IS30.12.2017
Précédent [2020/16]HU08.11.2011
AT30.08.2017
CY30.08.2017
CZ30.08.2017
DK30.08.2017
EE30.08.2017
FI30.08.2017
HR30.08.2017
LT30.08.2017
LV30.08.2017
MC30.08.2017
MK30.08.2017
NL30.08.2017
PL30.08.2017
RO30.08.2017
RS30.08.2017
SE30.08.2017
SI30.08.2017
SK30.08.2017
SM30.08.2017
TR30.08.2017
IE08.11.2017
LU08.11.2017
MT08.11.2017
BE30.11.2017
BG30.11.2017
CH30.11.2017
LI30.11.2017
NO30.11.2017
GR01.12.2017
IS30.12.2017
Précédent [2019/51]HU08.11.2011
AT30.08.2017
CY30.08.2017
CZ30.08.2017
DK30.08.2017
EE30.08.2017
FI30.08.2017
HR30.08.2017
LT30.08.2017
LV30.08.2017
MC30.08.2017
MK30.08.2017
NL30.08.2017
PL30.08.2017
RO30.08.2017
RS30.08.2017
SE30.08.2017
SI30.08.2017
SK30.08.2017
SM30.08.2017
IE08.11.2017
LU08.11.2017
MT08.11.2017
BE30.11.2017
BG30.11.2017
CH30.11.2017
LI30.11.2017
NO30.11.2017
GR01.12.2017
IS30.12.2017
Précédent [2019/46]HU08.11.2011
AT30.08.2017
CY30.08.2017
CZ30.08.2017
DK30.08.2017
EE30.08.2017
FI30.08.2017
HR30.08.2017
LT30.08.2017
LV30.08.2017
MC30.08.2017
NL30.08.2017
PL30.08.2017
RO30.08.2017
RS30.08.2017
SE30.08.2017
SI30.08.2017
SK30.08.2017
SM30.08.2017
IE08.11.2017
LU08.11.2017
MT08.11.2017
BE30.11.2017
BG30.11.2017
CH30.11.2017
LI30.11.2017
NO30.11.2017
GR01.12.2017
IS30.12.2017
Précédent [2019/31]HU08.11.2011
AT30.08.2017
CZ30.08.2017
DK30.08.2017
EE30.08.2017
FI30.08.2017
HR30.08.2017
LT30.08.2017
LV30.08.2017
MC30.08.2017
NL30.08.2017
PL30.08.2017
RO30.08.2017
RS30.08.2017
SE30.08.2017
SI30.08.2017
SK30.08.2017
SM30.08.2017
IE08.11.2017
LU08.11.2017
MT08.11.2017
BE30.11.2017
BG30.11.2017
CH30.11.2017
LI30.11.2017
NO30.11.2017
GR01.12.2017
IS30.12.2017
Précédent [2018/50]AT30.08.2017
CZ30.08.2017
DK30.08.2017
EE30.08.2017
FI30.08.2017
HR30.08.2017
LT30.08.2017
LV30.08.2017
MC30.08.2017
NL30.08.2017
PL30.08.2017
RO30.08.2017
RS30.08.2017
SE30.08.2017
SI30.08.2017
SK30.08.2017
SM30.08.2017
IE08.11.2017
LU08.11.2017
MT08.11.2017
BE30.11.2017
BG30.11.2017
CH30.11.2017
LI30.11.2017
NO30.11.2017
GR01.12.2017
IS30.12.2017
Précédent [2018/45]AT30.08.2017
CZ30.08.2017
DK30.08.2017
EE30.08.2017
FI30.08.2017
HR30.08.2017
LT30.08.2017
LV30.08.2017
MC30.08.2017
NL30.08.2017
PL30.08.2017
RO30.08.2017
RS30.08.2017
SE30.08.2017
SI30.08.2017
SK30.08.2017
SM30.08.2017
IE08.11.2017
LU08.11.2017
MT08.11.2017
BG30.11.2017
CH30.11.2017
LI30.11.2017
NO30.11.2017
GR01.12.2017
IS30.12.2017
Précédent [2018/43]AT30.08.2017
CZ30.08.2017
DK30.08.2017
EE30.08.2017
FI30.08.2017
HR30.08.2017
LT30.08.2017
LV30.08.2017
MC30.08.2017
NL30.08.2017
PL30.08.2017
RO30.08.2017
RS30.08.2017
SE30.08.2017
SI30.08.2017
SK30.08.2017
SM30.08.2017
LU08.11.2017
MT08.11.2017
BG30.11.2017
CH30.11.2017
LI30.11.2017
NO30.11.2017
GR01.12.2017
IS30.12.2017
Précédent [2018/39]AT30.08.2017
CZ30.08.2017
DK30.08.2017
EE30.08.2017
FI30.08.2017
HR30.08.2017
LT30.08.2017
LV30.08.2017
MC30.08.2017
NL30.08.2017
PL30.08.2017
RO30.08.2017
RS30.08.2017
SE30.08.2017
SI30.08.2017
SK30.08.2017
SM30.08.2017
LU08.11.2017
BG30.11.2017
CH30.11.2017
LI30.11.2017
NO30.11.2017
GR01.12.2017
IS30.12.2017
Précédent [2018/33]AT30.08.2017
CZ30.08.2017
DK30.08.2017
EE30.08.2017
FI30.08.2017
HR30.08.2017
LT30.08.2017
LV30.08.2017
MC30.08.2017
NL30.08.2017
PL30.08.2017
RO30.08.2017
RS30.08.2017
SE30.08.2017
SK30.08.2017
SM30.08.2017
BG30.11.2017
CH30.11.2017
LI30.11.2017
NO30.11.2017
GR01.12.2017
IS30.12.2017
Précédent [2018/24]AT30.08.2017
CZ30.08.2017
DK30.08.2017
EE30.08.2017
FI30.08.2017
HR30.08.2017
LT30.08.2017
LV30.08.2017
NL30.08.2017
PL30.08.2017
RO30.08.2017
RS30.08.2017
SE30.08.2017
SK30.08.2017
SM30.08.2017
BG30.11.2017
NO30.11.2017
GR01.12.2017
IS30.12.2017
Précédent [2018/23]AT30.08.2017
CZ30.08.2017
DK30.08.2017
EE30.08.2017
FI30.08.2017
HR30.08.2017
LT30.08.2017
LV30.08.2017
NL30.08.2017
PL30.08.2017
RO30.08.2017
RS30.08.2017
SE30.08.2017
SK30.08.2017
BG30.11.2017
NO30.11.2017
GR01.12.2017
IS30.12.2017
Précédent [2018/21]AT30.08.2017
CZ30.08.2017
DK30.08.2017
FI30.08.2017
HR30.08.2017
LT30.08.2017
LV30.08.2017
NL30.08.2017
RS30.08.2017
SE30.08.2017
BG30.11.2017
NO30.11.2017
GR01.12.2017
IS30.12.2017
Précédent [2018/15]AT30.08.2017
FI30.08.2017
HR30.08.2017
LT30.08.2017
LV30.08.2017
NL30.08.2017
RS30.08.2017
SE30.08.2017
BG30.11.2017
NO30.11.2017
GR01.12.2017
IS30.12.2017
Précédent [2018/12]AT30.08.2017
FI30.08.2017
HR30.08.2017
LT30.08.2017
LV30.08.2017
RS30.08.2017
SE30.08.2017
BG30.11.2017
NO30.11.2017
GR01.12.2017
IS30.12.2017
Précédent [2018/11]AT30.08.2017
FI30.08.2017
HR30.08.2017
LT30.08.2017
RS30.08.2017
SE30.08.2017
BG30.11.2017
NO30.11.2017
GR01.12.2017
IS30.12.2017
Précédent [2018/10]AT30.08.2017
FI30.08.2017
HR30.08.2017
LT30.08.2017
RS30.08.2017
SE30.08.2017
NO30.11.2017
Précédent [2018/09]FI30.08.2017
LT30.08.2017
SE30.08.2017
NO30.11.2017
Précédent [2018/08]FI30.08.2017
LT30.08.2017
NO30.11.2017
Précédent [2018/07]LT30.08.2017
NO30.11.2017
Cité dansRecherche internationale[A]WO2004029055  (BAYER HEALTHCARE AG [DE], et al) [A] 1-17* claim 1 *;
 [ID]WO2008070150  (BAYER PHARMACEUTICALS CORP [US], et al) [ID] 1-17 * page 80; example 11; claim 1 *;
 [I]WO2010034414  (BAYER SCHERING PHARMA AG [DE], et al) [I] 1-17 * page 21; example Ia; claim 1 *
par le demandeurUS5011472
 US5023252
 WO2008070150
    - PURE APPL CHEM, (1976), vol. 45, pages 11 - 30
    - S. M. BERGE ET AL., "Pharmaceutical Salts", J. PHARM. SCI., (1977), vol. 66, doi:doi:10.1002/jps.2600660104, pages 1 - 19, XP002675560

DOI:   http://dx.doi.org/10.1002/jps.2600660104
    - Organic Reactions, JOHN WILEY
    - Organic Syntheses, JOHN WILEY
    - Reagents for Organic Synthesis, JOHN WILEY
    - The Total Synthesis of Natural Products, JOHN WILEY
    - The Organic Chemistry of Drug Synthesis, JOHN WILEY
    - Annual Reports in Organic Synthesis, ACADEMIC PRESS
    - HOUBEN-WEYL, Methoden der Organischen Chemie, THIEME
    - SCIFINDER, Handbuch der Organischen Chemie
    - "The ACS Style Guide", Guidelines for Authors for the Journal of Organic Chemistry
    - POWELL, M. F. ET AL., "Compendium of Excipients for Parenteral Formulations", PDA JOURNAL OF PHARMACEUTICAL SCIENCE & TECHNOLOGY, (1998), vol. 52, no. 5, pages 238 - 311, XP009119027
    - STRICKLEY, R.G, "Parenteral Formulations of Small Molecule Therapeutics Marketed in the United States", PDA JOURNAL OF PHARMACEUTICAL SCIENCE & TECHNOLOGY 1999, (1999), vol. 53, no. 6, pages 324 - 349
    - NEMA, S., "Excipients and Their Use in Injectable Products", PDA JOURNAL OF PHARMACEUTICAL SCIENCE
    - GOODMAN, GILMAN'S, The Pharmacological Basis of Therapeutics, MCGRAW-HILL, (1996), pages 1225 - 1287
    - AIELLO ET AL., NEW ENGL. J. MED., (1994), vol. 331, page 1480
    - PEER ET AL., LAB. INVEST., (1995), vol. 72, page 638
    - LOPEZ ET AL., INVEST. OPTHTHALMOL. VIS. SCI., (1996), vol. 37, page 855
    - "Multiple signaling pathways converge on p-catenin in thyroid cancer", ABBOSH, P.H., NEPHEW, K.P., Thyroid, (2005), vol. 15, pages 551 - 561
    - AIELLO, L.P., AVERY, R.L., ARRIGG, P.G., KEYT, B.A., JAMPEL, H.D., SHAH, S.T., PASQUALE, L.R., THIEME, H., IWAMOTO, M.A., PARK, J., "Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders", N. ENGL. J. MED., (1994), vol. 331, doi:doi:10.1056/NEJM199412013312203, pages 1480 - 1487, XP002690192

DOI:   http://dx.doi.org/10.1056/NEJM199412013312203
    - ALI, I.U., SCHRIML, L.M., DEAN, M. J., "Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity", NATL. CANCER LNST., (1999), vol. 91, pages 1922 - 1932
    - BACHMAN, K.E., ARGANI, P., SAMUELS, Y., SILLIMAN, N., PTAK, J., SZABO, S., KONISHI, H., KARAKAS, B., BLAIR, B.G., LIN, C., "The PIK3CA gene is mutated with high frequency in human breast cancers", CANCER BIOL. THERAP., (2004), vol. 3, doi:doi:10.4161/cbt.3.8.994, pages 772 - 775, XP055035716

DOI:   http://dx.doi.org/10.4161/cbt.3.8.994
    - BADER, A.G., KANG, S.;, VOGT, P.K., "Cancer-specific mutations in PIK3CA are oncogenic in vivo", PROC. NATL. ACAD. SCI. U.S.A., (2006), vol. 103, doi:doi:10.1073/PNAS.0510857103, pages 1475 - 1479, XP002687647

DOI:   http://dx.doi.org/10.1073/PNAS.0510857103
    - BARTHWAL, M.K., SATHYANARAYANA, P., KUNDU, C.N., RANA, B., PRADEEP, A., SHARMA, C., WOODGETT, J.R., RANA, A, "Negative Regulation of Mixed Lineage Kinase 3 by Protein Kinase B/AKT Leads to Cell Survival", J. BIOL. CHEM., (2003), vol. 278, pages 3897 - 3902
    - BÉNISTANT, C., CHAPUIS, H., ROCHE, S., "A specific function for phosphatidylinositol 3-kinase a (p85?-p110?) in cell survival and for phosphatidylinositol 3- kinase p (p85a-p110p) in de novo DNA synthesis of human colon carcinoma cells", ONCOGENE, (2000), vol. 19, doi:doi:10.1038/sj.onc.1203871, pages 5083 - 5090, XP002484274

DOI:   http://dx.doi.org/10.1038/sj.onc.1203871
    - BISSERY, M.-C., NOHYNEK, G., SANDERINK, G.-J., LAVELLE, F., "Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: preclinical experience", ANTI-CANCER DRUGS, (1995), vol. 6, pages 339 - 355
    - BRODERICK, D.K., DI, C., PARRETT, T.J., SAMUELS, Y.R., CUMMINS, J.M., MCLENDON, R.E., FULTS, D.W., VELCULESCU, V.E., BIGNER, D.D.,, "Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas", CANCER RES., (2004), vol. 64, doi:doi:10.1158/0008-5472.CAN-04-1170, pages 5048 - 5050, XP002517093

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-04-1170
    - BROWN, R.A., SHEPHERD, P.R., "Growth factor regulation of the novel class II phosphoinositide 3-kinases", BIOCHEM. SOC. TRANS., (2001), vol. 29, pages 535 - 537
    - BRUGGE, J., HUNG, M.-C., MILLS, G.B., "A new mutational aktivation in the P13K pathway", CANCER CELL, (2007), vol. 12, pages 104 - 107
    - BRUNET, A., BONNI, A., ZIGMOND, M.J., LIN, M.Z., JUO, P., HU, L.S., ANDERSON, M.J., ARDEN, K.C., BLENIS, J., GREENBERG, M.E, "Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor", CELL, (1999), vol. 96, doi:doi:10.1016/S0092-8674(00)80595-4, pages 857 - 868, XP002922384

DOI:   http://dx.doi.org/10.1016/S0092-8674(00)80595-4
    - BYUN, D.-S., CHO, K., RYU, B.-K., LEE, M.-G., PARK, J.-I., CHAE, K.-S., KIM, H.-J., CHI, S.-G., "Frequent monoallelic deletion of PTEN and its reciprocal association with PIK3CA amplification in gastric carcinoma", INT. J. CANCER, (2003), vol. 104, pages 318 - 327
    - CAMPBELL, I.G., RUSSELL, S.E., CHOONG, D.Y.H., MONTGOMERY, K.G., CIAVARELLA, M.L., HOOI, C.S.F., CRISTIANO, B.E., PEARSON, R.B., P, "Mutation of the PIK3CA gene in ovarian and breast cancer", CANCER RES., (2004), vol. 64, pages 7678 - 7681
    - CARDONE, M.H., ROY, N., STENNICKE, H.R., SALVESEN, G.S., FRANKE, T.F., STANBRIDGE, E., FRISCH, S., REED, J.C., "Regulation of cell death protease caspase-9 by phosphorylation", SCIENCE, (1998), vol. 282, pages 1318 - 1321
    - CHEN, Y.L., LAW, P.-Y., LOH, H.H., "Inhibition of P!3K/Akt signaling: An emerging paradigm for targeted cancer therapy", CURR. MED. CHEM.: ANTI-CANCER AGENTS, (2005), vol. 5, pages 575 - 589, XP009098139
    - CIECHOMSKA, I., PYRZYNSKA, B., KAZMIERCZAK, P., KAMINSKA, B., "Inhibition of Akt kinase signalling and activation of Forkhead are indispensable for up- regulation of FasL expression in apoptosis of glioma cells", ONCOGENE, (2003), vol. 22, pages 7617 - 7627
    - CROSS, D.A.E., ALESSI, D.R, COHEN, P., ANDJELKOVICH, M., HEMMINGS, B.A., "Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B", NATURE, (1995), vol. 378, doi:doi:10.1038/378785a0, pages 785 - 789, XP002025954

DOI:   http://dx.doi.org/10.1038/378785a0
    - CULLY, M., YOU, H., LEVINE, A.J., MAK, T.W., "Beyond PTEN mutations: the P13K pathway as an integrator of multiple inputs during tumorigenesis", NAT. REV. CANCER, (2006), vol. 6, pages 184 - 192
    - CZAUDERNA, F., FECHTNER, M., AYGUN, H., ARNOLD, W., KLIPPEL, A., GIESE, K., KAUFMANN, J., "Functional studies of the PI(3)-kinase signalling pathway employing synthetic and expressed siRNA", NUCLEIC ACIDS RES., (2003), vol. 31, doi:doi:10.1093/nar/gkg141, pages 670 - 682, XP002992229

DOI:   http://dx.doi.org/10.1093/nar/gkg141
    - DALY, C, WONG, V., BUROVA, E., WEI, Y., ZABSKI, S., GRIFFITHS, J., LAI, K.-M., LIN, H.C., LOFFE, E., YANCOPOULOS, G.D., "Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOX01", GENES DEV., (2004), vol. 18, pages 1060 - 1071
    - DEL PESO, L., GONZAIEZ-GARCIA, M., PAGE, C., HERRERA, R., NUNEZ, G., "Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt", SCIENCE, (1997), vol. 278, pages 687 - 689, XP002958941
    - DIEHL, J.A., CHENG, M., ROUSSEL, M.F.;, SHERR, C.J., "Glycogen synthase kinase-3b regulates cyclin D1 proteolysis and subcellular localization", GENES DEV., (1998), vol. 12, pages 3499 - 3511
    - DIJKERS, P.F., MEDEMA, R.H., LAMMERS, J.-W.J., KOENDERMAN, L., COFFER, P.J., "Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the Forkhead transcription factor FKHR-L1", CURR. BIOL., (2000), vol. 10, pages 1201 - 1204
    - DOMIN, J., WATERFIELD, M.D., "Using structure to define the function of phosphoinositide 3-kinase family members", FEBS LETT., (1997), vol. 410, doi:doi:10.1016/S0014-5793(97)00617-0, pages 91 - 95, XP004261759

DOI:   http://dx.doi.org/10.1016/S0014-5793(97)00617-0
    - DOWNES, C.P., GRAY, A., LUCOCQ, J.M., "Probing phosphoinositide functions in signaling and membrane trafficking", TRENDS CELL BIOL., (2005), vol. 15, doi:doi:10.1016/j.tcb.2005.03.008, pages 259 - 268, XP004872259

DOI:   http://dx.doi.org/10.1016/j.tcb.2005.03.008
    - EDELMAN, M.J., GANDARA, D.R., "Promising new agents in the treatment of non-small cell lung cancer", CANCER CHEMOTHERAP. PHARMACOL., (1996), vol. 37, pages 385 - 393
    - FIGUEROA, C., TARRAS, S., TAYLOR, J., VOJTEK, A.B., "Akt2 negatively regulates assembly of the POSH-MLK-JNK signaling complex", J. BIOL. CHEM., (2003), vol. 278, doi:doi:10.1074/jbc.M307357200, pages 47922 - 47927, XP002996244

DOI:   http://dx.doi.org/10.1074/jbc.M307357200
    - FLEMING, I.N., GRAY, A., DOWNES, C.P., "Regulation of the Rac1-specific exchange factor tiam1 involves both phosphoinositide 3-kinase-dependent and - independent components", BIOCHEM. J., (2000), vol. 351, pages 173 - 182
    - FUNAKI, M., KATAGIRI, H., INUKAI, K., KIKUCHI, M., ASANO, T., "Structure and function of phosphatidylinositol-3,4 kinase", CELL. SIGNALLING, (2000), vol. 12, pages 135 - 142
    - GALLIA, G.L., RAND, V., SIU, I.M., EBERHART, C.G., JAMES, C.D., MARIE, S.K.N., OBA-SHINJO, S.M., CARLOTTI, C.G., CABALLERO, O.L.,, "PIK3CA gene mutations in pediatric and adult glioblastoma multiforme", MOL. CANCER RES., (2006), vol. 4, pages 709 - 714
    - GARCIA-ROSTAN, G., COSTA, A.M., PEREIRA-CASTRO, I., SALVATORE, G., HERNANDEZ, R.;, HERMSEM, M.J.A., HERRERO, A., FUSCO, A., CAMESE, "Mutation of the PIK3CA gene in anaplastic thyroid cancer", CANCER RES., (2005), vol. 65, pages 10199 - 10207
    - GERSHTEIN, E.S., SHATSKAYA, V.A., ERMILOVA, V.D., KUSHLINSKY, N.E., KRASIL'NIKOV, M.A., "Phosphatidylinositol 3-kinase expression in human breast cancer", CLIN. CHIM. ACTA, (1999), vol. 287, pages 59 - 67
    - GOTTSCHALK, A.R., DOAN, A., NAKAMURA, J.L., STOKOE, D., HAAS-KOGAN, D.A, "Inhibition of phosphatidylinositol-3-kinase causes increased sensitivity to radiation through a PKB-dependent mechanism", INT. J. RADIAT. ONCOL. BIOL. PHYS., (2005), vol. 63, doi:doi:10.1016/j.ijrobp.2005.08.014, pages 1221 - 1227, XP025262460

DOI:   http://dx.doi.org/10.1016/j.ijrobp.2005.08.014
    - GUPTA, A.K., CERNIGLIA, G.J., MICK, R., AHMED, M.S., BAKANAUSKAS, V.J., MUSCHEL, R.J., MCKENNA, W.G., "Radiation sensitization of human cancer cells in vivo by inhibiting the activity of P13K using LY294002", INT. J. RADIAT. ONCOL. BIOL. PHYS., (2003), vol. 56, doi:doi:10.1016/S0360-3016(03)00214-1, pages 846 - 853, XP002327025

DOI:   http://dx.doi.org/10.1016/S0360-3016(03)00214-1
    - HAAS-KOGAN, D., SHALEV, N., WONG, M., MILLS, G., YOUNT, G., STOKOE, D., "Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC", CURR. BIOL., (1998), vol. 8, pages 1195 - 1198
    - HARTMANN, C., BARTELS, G., GEHLHAAR, C., HOLTKAMP, N., VON DEIMLING, A., "PIK3CA mutations in glioblastoma multiforme", ACTA NEUROPATHOL., (2005), vol. 109, doi:doi:10.1007/s00401-005-1000-1, pages 639 - 642, XP019340738

DOI:   http://dx.doi.org/10.1007/s00401-005-1000-1
    - HENNESSY, B.T., SMITH, D.L., RAM, P.T., LU, Y., MILLS, G.B., "Exploiting the P!3K/AKT Pathway for Cancer Drug Discovery", NAT. REV. DRUG DISC., (2005), vol. 4, pages 988 - 1004
    - HODGKINSON, C.P., SALE, E.M., SALE, G.J., "Characterization of PDK2 activity against Protein Kinase B gamma", BIOCHEMISTRY, (2002), vol. 41, doi:doi:10.1021/bi026065r, pages 10351 - 10359, XP002409946

DOI:   http://dx.doi.org/10.1021/bi026065r
    - HRESKO, R.C., MURATA, H., MUECKLER, M., "Phosphoinositide-dependent Kinase-2 is a distinct protein kinase enriched in a novel cytoskeletal fraction associated with adipocyte plasma membranes", J. BIOL. CHEM., (2003), vol. 278, pages 21615 - 21622
    - HUANG, C., MA, W.-Y., DONG, Z., "Requirement for phosphatidylinositol 3-kinase in epidermal growth factor-induced AP-1 transactivation and transformation in JB6 P+ cells", MOL. CELL. BIOL., (1996), vol. 16, pages 6427 - 6435
    - HUPP, T.R., LANE, D.P.;, BALL, K.L., "Strategies for manipulating the p53 pathway in the treatment of human cancer", BIOCHEM. J., (2000), vol. 352, pages 1 - 17
    - LHLE, N.T., WILLIAMS, R., CHOW, S., CHEW, W., BERGGREN, M.I., PAINE-MURRIETA, G., MINION, D.J., HALTER, R.J., WIPF, P., ABRAHAM, R, "Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling", MOL. CANCER THER., (2004), vol. 3, pages 763 - 772, XP002532313
    - IKENOUE, T., KANAI, F., HIKIBA, Y., OBATA, T., TANAKA, Y., IMAMURA, J., OHTA, M., JAZAG, A., GULENG, B., TATEISHI, K., "Functional analysis of PIK3CA gene mutations in human colorectal cancer", CANCER RES., (2005), vol. 65, pages 4562 - 4567
    - ISHII, N., MAIER, D., MERLO, A., TADA, M., SAWAMURA, Y.;, DISERENS, A.-C., VAN MEIR, E.G., "Frequent co-alterations of TP53, p16/CDKN2A, pl4ARF, PTEN tumor suppressor genes in human glioma cell lines", BRAIN PATHOL., (1999), vol. 9, pages 469 - 479
    - ITOH, T., TAKENAWA, T., "Phosphoinositide-binding domains. Functional units for temporal and spatial regulation of intracellular signalling", CELL. SIGNALLING, (2002), vol. 14, pages 733 - 743
    - JANSSEN, J.W.G., SCHLEITHOFF, L., BARTRAM, C.R., SCHULZ, A.S., "An oncogenic fusion product of the phosphatidylinositol 3-kinase p85b subunit and HUMORF8, a putative deubiquitinating enzyme", ONCOGENE, (1998), vol. 16, pages 1767 - 1772
    - JIA, S., LIU, Z., ZHANG, S., LIU, P., ZHANG, L., LEE, S.H., ZHANG, J., SIGNORETTI, S., LODA, M., ROBERTS, T.M., "Essential roles of PI(3)K-p110(3 in cell growth, metabolism and tumorigenesis", NATURE, (2008), vol. 454, pages 776 - 779
    - JIA, S., ROBERTS, T.M., ZHAO, J.J., "Should individual P13 kinase isoforms be targeted in cancer?", CURR. OPIN. CELL BIOL., (2009), vol. 21, doi:doi:10.1016/j.ceb.2008.12.007, pages 199 - 208, XP026035452

DOI:   http://dx.doi.org/10.1016/j.ceb.2008.12.007
    - JIMENEZ, C., JONES, D.R., RODRIGUEZ-VICIANA, P., GONZALEZ-GARCIA, A., LEONARDO, E., WENNSTROM, S., VON KOBBE, C., TORAN, J.L., R.-, "Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase", EMBO J., (1998), vol. 17, pages 743 - 753
    - JUCKER, M., SUDEL, K., HORN, S., SICKEL, M., WEGNER, W., FIEDLER, W., FELDMAN, R.A., "Expression of a mutated form of the p85a regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin's lymphoma-derived cell line (CO", LEUKEMIA, (2002), vol. 16, pages 894 - 901
    - KANG, S., BADER, A.G., VOGT, P.K., "Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic", PROC. NATL. ACAD. SCI. U.S.A., (2005), vol. 102, pages 802 - 807
    - KANG, S., DENLEY, A., VANHAESEBROECK, B., VOGT, P.K., "Oncogenic transformation induced by the p110b, -g, and -d isoforms of class I phosphoinositide 3-kinase", PROC. NATL. ACAD. SCI. U.S.A., (2006), vol. 103, pages 1289 - 1294
    - KATSO, R., OKKENHAUG, K., AHMADI, K., WHITE, S.;, TIMMS, J., WATERFIELD, M.D., "Cellular function of phosphoinositide 3-kinases: implications for development, immunity, homeostasis, and cancer", ANN. REV. CELL. DEV. BIOL., (2001), vol. 17, pages 615 - 675
    - KIM, A.H., KHURSIGARA, G., SUN, X., FRANKE, T.F., CHAO, M.V., "Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1", MOL. CELL. BIOL., (2001), vol. 21, pages 893 - 901
    - KIM, D., DAN, H.C., PARK, S., YANG, L., LIU, Q., KANEKO, S., NING, J., HE, L., YANG, H., SUN, M., "AKT/PKB signaling mechanisms in cancer and chemoresistance", FRONT. BIOSCI., (2005), vol. 10, doi:doi:10.2741/1592, pages 975 - 987, XP009166431

DOI:   http://dx.doi.org/10.2741/1592
    - KLIPPEL, A., KAVANAUGH, W.M., POT, D., WILLIAMS, L.T., "A specific product of phosphatidylinositol 3-kinase directly activates the protein kinase Akt through its pleckstrin homology domain", MOL. CELL. BIOL., (1997), vol. 17, pages 338 - 344
    - KODAKI, T., WOSCHOLSKI, R., HALLBERG, B., RODRIGUEZ-VICIANA, P., DOWNWARD, J., PARKER, P.J., "The activation of phosphatidylinositol 3-kinase by Ras", CURR. BIOL., (1994), vol. 4, doi:doi:10.1016/S0960-9822(00)00177-9, pages 798 - 806, XP024249253

DOI:   http://dx.doi.org/10.1016/S0960-9822(00)00177-9
    - KOPS, G.J.P.L., DE RUITER, N.D., DE VRIES-SMITS, A.M.M., POWELL, D.R., BOS, J.L., BURGERING, B.M.T, "Direct control of the Forkhead transcription factor AFX by protein kinase B", NATURE, (1999), vol. 398, doi:doi:10.1038/19328, pages 630 - 634, XP000955388

DOI:   http://dx.doi.org/10.1038/19328
    - LEE, J.T., JR., STEELMAN, L.S., MCCUBREY, J.A., "Phosphatidylinositol 3'-Kinase Activation Leads to Multidrug Resistance Protein-1 Expression and Subsequent Chemoresistance in Advanced Prostate Cancer Cells", CANCER RES., (2004), vol. 64, pages 8397 - 8404
    - LEE, J.W., SOUNG, Y.H., KIM, S.Y., LEE, H.W., PARK, W.S., NAM, S.W., KIM, S.H., LEE, J.Y., YOO, N.J., LEE, S.H., "PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas", ONCOGENE, (2005), vol. 24, pages 1477 - 1480
    - LEMMON, M.A., "Phosphoinositide recognition domains", TRAFFIC, (2003), vol. 4, pages 201 - 213
    - LEVINE, D.A., BOGOMOLNIY, F., YEE, C.J., LASH, A., BARAKAT, R.R., BORGEN, P.I., BOYD, J., "Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers", CLIN. CANCER RES., (2005), vol. 11, doi:doi:10.1158/1078-0432.CCR-04-2142, pages 2875 - 2878, XP055035718

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-04-2142
    - LI, J., YEN, C., LIAW, D., PODSYPANINA, K., BOSE, S., WANG, S.I., PUC, J., MILIARESIS, C., RODGERS, L., MCCOMBIE, R.;, "PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer", SCIENCE, (1997), vol. 275, pages 1943 - 1947
    - LI, V.S.W., WONG, C.W., CHAN, T.L., CHAN, A.S.W., ZHAO, W., CHU, K.-M., SO, S., CHEN, X., YUEN, S.T., LEUNG, S.Y., "Mutations of PIK3CA in gastric adenocarcinoma", BMC CANCER, (2005), vol. 5, doi:doi:10.1186/1471-2407-5-29, page 29, XP021004788

DOI:   http://dx.doi.org/10.1186/1471-2407-5-29
    - LI, Y.-L., TIAN, Z., WU, D.-Y., FU, B.-Y., XIN, Y., "Loss of heterozygosity on 1 Oq23.3 and mutation of tumor suppressor gene PTEN in gastric cancer and precancerous lesions", WORLD J. GASTROENTEROL., (2005), vol. 11, pages 285 - 288
    - LIAO, Y., HUNG, M.-C., "Regulation of the activity of p38 mitogen-activated protein kinase by Akt in cancer and adenoviral protein E1A-mediated sensitization to apoptosis", MOL. CELL. BIOL., (2003), vol. 23, pages 6836 - 6848
    - LIU, P., CHENG, H., ROBERTS, T.M., ZHAO, J.J., "Targeting the phosphoinositide 3-kinase pathway in cancer", NAT. REV. DRUG DISC., (2009), vol. 8, doi:doi:10.1038/nrd2926, pages 627 - 644, XP055020926

DOI:   http://dx.doi.org/10.1038/nrd2926
    - LOPEZ-ILASACA, M., LI, W., UREN, A., YU, J.-C., KAZLAUSKAS, A., GUTKIND, J.S., HEIDARAN, M.A., "Requirement of phosphatidylinositol-3 kinase for activation of JNK/SAPKs by PDGF", BIOCHEM BIOPHYS. RES. COMMUN., (1997), vol. 232, pages 273 - 277
    - LOPEZ, P.F., SIPPY, B.D., LAMBERT, H.M., THACH, A.B., HINTON, D.R., "Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration- related choroidal neovascular membranes", INVEST. OPHTHALMOL. VIS. SCI., (1996), vol. 37, pages 855 - 868
    - MA, Y.-Y., WEI, S.-J., LIN, Y.-C., LUNG, J.-C., CHANG, T.-C., WHANG-PENG, J., LIU, J.M., YANG, D.-M., YANG, W.K, SHEN, C.-Y., "PIK3CA as an oncogene in cervical cancer", ONCOGENE, (2000), vol. 19, pages 2739 - 2744
    - MAYO, L.D., DIXON, J.E., DURDEN, D.L., TONKS, N.K., DONNER, D.B., "PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy", J. BIOL. CHEM., (2002), vol. 277, pages 5484 - 5489
    - MOMAND, J., WU, H.-H., DASGUPTA, G., "MDM2 - master regulator of the p53 tumor suppressor protein", GENE, (2000), vol. 242, doi:doi:10.1016/S0378-1119(99)00487-4, pages 15 - 29, XP004196500

DOI:   http://dx.doi.org/10.1016/S0378-1119(99)00487-4
    - MOTTI, M.L., DE MARCO, C., CALIFANO, D., FUSCO, A., VIGLIETTO, G., "Akt-dependent T198 phosphorylation of cyclin-dependent kinase inhibitor p27kip1 in breast cancer", CELL CYCLE, (2004), vol. 3, pages 1074 - 1080
    - MYERS, M.P., PASS, I., BATTY, I.H., VAN DER KAAY, J., STOLAROV, J.P., HEMMINGS, B.A., WIGLER, M.H., DOWNES, C.P., TONKS, N.K., "The lipid phosphatase activity of PTEN is critical for its tumor suppressor function", PROC. NATL. ACAD. SCI. U.S.A., (1998), vol. 95, doi:doi:10.1073/pnas.95.23.13513, pages 13513 - 13518, XP000861905

DOI:   http://dx.doi.org/10.1073/pnas.95.23.13513
    - NAGATA, Y., LAN, K.-H., ZHOU, X., TAN, M., ESTEVA, F.J., SAHIN, A.A., KLOS, K.S., LI, P., MONIA, B.P., NGUYEN, N.T., "PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients", CANCER CELL, (2004), vol. 6, pages 117 - 127
    - NAITO, A.T., AKAZAWA, H., TAKANO, H., MINAMINO, T., NAGAI, T., ABURATANI, H., KOMURO, I., "Phosphatidylinositol 3-Kinase-Akt Pathway Plays a Critical Role in Early Cardiomyogenesis by Regulating Canonical Wnt Signaling", CIRC. RES., (2005), vol. 97, doi:doi:10.1161/01.RES.0000175241.92285.f8, pages 144 - 151, XP003018975

DOI:   http://dx.doi.org/10.1161/01.RES.0000175241.92285.f8
    - NEMA, S., WASHKUHN, R.J., BRENDEL, R.J., "Excipients and their use in injectable products", PDA J. PHARM. SCI. TECHNOL., (1997), vol. 51, pages 166 - 171
    - ODA, K., STOKOE, D., TAKETANI, Y., MCCORMICK, F., "High Frequency of Coexistent Mutations of PIK3CA and PTEN Genes in Endometrial Carcinoma", CANCER RES., (2005), vol. 65, doi:doi:10.1158/0008-5472.CAN-05-2620, pages 10669 - 10673, XP055268548

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-05-2620
    - OGAWARA, Y., KISHISHITA, S., OBATA, T., ISAZAWA, Y., SUZUKI, T., TANAKA, K., MASUYAMA, N., GOTOH, Y., "Akt enhances Mdm2-mediated ubiquitination and degradation of p53", J. BIOL. CHEM., (2002), vol. 277, pages 21843 - 21850
    - OKI, E., KAKEJI, Y., BABA, H., TOKUNAGA, E., NAKAMURA, T., UEDA, N., FUTATSUGI, M., YAMAMOTO, M., IKEBE, M., MAEHARA, Y., "Impact of loss of heterozygosity of encoding phosphate and tensin homolog on the prognosis of gastric cancer", J. GASTROENTEROL. HEPATOL., (2006), vol. 21, pages 814 - 818
    - OLSON, J.M., HALLAHAN, A.R., "p38 MAP kinase: a convergence point in cancer therapy", TRENDS MOL. MED., (2004), vol. 10, pages 125 - 129
    - OSAKI, M., OSHIMURA, M., ITO, H., "PI3K-Akt pathway: Its functions and alterations in human cancer", APOPTOSIS, (2004), vol. 9, doi:doi:10.1023/B:APPT.0000045801.15585.dd, pages 667 - 676, XP019204869

DOI:   http://dx.doi.org/10.1023/B:APPT.0000045801.15585.dd
    - PASTORINO, J.G., TAFANI, M., FARBER, J.L., "Tumor necrosis factor induces phosphorylation and translocation of BAD through a phosphatidylinositide-3-OH kinase-dependent pathway", J. BIOL. CHEM., (1999), vol. 274, pages 19411 - 19416
    - PENDARIES, C., TRONCHERE, H., PLANTAVID, M., PAYRASTRE, B., "Phosphoinositide signaling disorders in human diseases", FEBS LETT., (2003), vol. 546, doi:doi:10.1016/S0014-5793(03)00437-X, pages 25 - 31, XP004433615

DOI:   http://dx.doi.org/10.1016/S0014-5793(03)00437-X
    - PHILLIPS, W.A., ST. CLAIR, F., MUNDAY, A.D., THOMAS, R.J.S., MITCHELL, C.A., "Increased levels of phosphatidylinositol 3-kinase activity in colorectal tumors", CANCER, (1998), vol. 83, pages 41 - 47
    - PHILP, A.J., CAMPBELL, I.G., LEET, C., VINCAN, E., ROCKMAN, S.P., WHITEHEAD, R.H., THOMAS, R.J.S., PHILLIPS, W.A., "The phosphatidylinositol 3'-kinase p85a gene is an oncogene in human ovarian and colon tumors", CANCER RES., (2001), vol. 61, pages 7426 - 7429, XP002505603
    - POWELL, M.F., NGUYEN, T., BALOIAN, L., "Compendium of excipients for parenteral formulations", PDA J. PHARM. SCI. TECHNOL., (1998), vol. 52, pages 238 - 311, XP009119027
    - POWIS, G., BONJOUKLIAN, R., BERGGREN, M.M., GALLEGOS, A., ABRAHAM, R., ASHENDEL, C., ZALKOW, L., MATTER, W.F., DODGE, J., "Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase", CANCER RES., (1994), vol. 54, pages 2419 - 2423
    - PU, P., KANG, C., ZHANG, Z., LIU, X., JIANG, H., "Downregulation of PIK3CB by siRNA suppresses malignant glioma cell growth in vitro and in vivo", TECHNOL. CANCER RES. TREAT., (2006), vol. 5, pages 271 - 280, XP008092957
    - RAHIMI, N., TREMBLAY, E., ELLIOTT, B., "Phosphatidylinositol 3-kinase activity is required for hepatocyte growth factor-induced mitogenic signals in epithelial cells", J. BIOL. CHEM., (1996), vol. 271, pages 24850 - 24855
    - ROCHE, S., DOWNWARD, J., RAYNAL, P., COURTNEIDGE, S.A., "A function for phosphatidylinositol 3-kinase b (p85a-p110b) in fibroblasts during mitogenesis: requirement for insulin- and lysophosphatidic acid-mediated signal transduction", MOL. CELL. BIOL., (1998), vol. 18, pages 7119 - 7129
    - ROCHE, S., KOEGL, M., COURTNEIDGE, S.A., "The phosphatidylinositol 3-kinase a is required for DNA synthesis induced by some, but not all, growth factors", PROC. NATL. ACAD. SCI. U.S.A., (1994), vol. 91, pages 9185 - 9189
    - ROMASHKOVA, J.A., MAKAROV, S.S., "Nf-kB is a target of Akt in anti- apoptotic PDGF signalling", NATURE, (1999), vol. 401, pages 86 - 90
    - SAAL, L.H., HOLM, K., MAURER, M., MEMEO, L., SU, T., WANG, X., YU, J.S., MALMSTROEM, P.-O., MANSUKHANI, M., ENOKSSON, J., "PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma", CANCER RES., (2005), vol. 65, doi:doi:10.1158/0008-5472-CAN-04-3913, pages 2554 - 2559, XP055070087

DOI:   http://dx.doi.org/10.1158/0008-5472-CAN-04-3913
    - SAMUELS, Y., DIAZ, L.A., JR., SCHMIDT-KITTLER, 0., CUMMINS, J.M., DELONG, L., CHEONG, I., RAGO, C., HUSO, D.L., LENGAUER, C., KINZ, "Mutant PIK3CA promotes cell growth and invasion of human cancer cells", CANCER CELL, (2005), vol. 7, doi:doi:10.1016/J.CCR.2005.05.014, pages 561 - 573, XP002729908

DOI:   http://dx.doi.org/10.1016/J.CCR.2005.05.014
    - SAMUELS, Y., ERICSON, K., "Oncogenic P13K and its role in cancer", CURR. OPIN. ONCOL., (2006), vol. 18, doi:doi:10.1097/01.cco.0000198021.99347.b9, pages 77 - 82, XP009172157

DOI:   http://dx.doi.org/10.1097/01.cco.0000198021.99347.b9
    - SAMUELS, Y., WANG, Z., BARDELLI, A., SILLIMAN, N., PTAK, J., SZABO, S., YAN, H., GAZDAR, A., POWELL, S.M., RIGGINS, G.J., "Brevia: High frequency of mutations of the PIK3Ca gene in human cancers", SCIENCE, (2004), vol. 304, page 554
    - SCHEID, M.P., MARIGNANI, P.A., WOODGETT, J.R., "Multiple phosphoinositide 3-kinase-dependent steps in activation of protein kinase B", MOL. CELL. BIOL., (2002), vol. 22, pages 6247 - 6260
    - SCHULTZ, R.M., MERRIMAN, R.L., ANDIS, S.L., BONJOUKLIAN, R., GRINDEY, G.B., RUTHERFORD, P.G., GALLEGOS, A., MASSEY, K., POWIS, G., "In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin", ANTICANCER RES., (1995), vol. 15, pages 1135 - 1139, XP009116931
    - SEGRELLES, C., MORAL, M., LARA, M.F., RUIZ, S., SANTOS, M., LEIS, H., GARCIA-ESCUDERO, R., MARTINEZ-CRUZ, A.B., MARTINEZ-PALACIO,, "Molecular determinants of Akt-induced keratinocyte transformation", ONCOGENE, (2006), vol. 25, pages 1174 - 1185
    - SEKIMOTO, T., FUKUMOTO, M., YONEDA, Y., "14-3-3 suppresses the nuclear localization of threonine 157-phosphorylated p27Kip1", EMBO J., (2004), vol. 23, pages 1934 - 1942
    - SEMBA, S., ITOH, N., ITO, M., YOUSSEF, E.M., HARADA, M., MORIYA, T., KIMURA, W., YAMAKAWA, M., "Down-regulation of PIK3CG catalytic subunit of phosphatidylinositol 3-OH kinase by CpG hypermethylation in human colorectal carcinoma", CLIN. CANCER RES., (2002), vol. 8, pages 3824 - 3831, XP055231234
    - SHAYESTEH, L., LU, Y., KUO, W.-L., BALDOCCHI, R., GODFREY, T., COLLINS, C., PINKEL, D., POWELL, B., MILLS, G.B., GRAY, J.W., "PIK3CA is implicated as an oncogene in ovarian cancer", NAT. GENET., (1999), vol. 21, doi:doi:10.1038/5042, pages 99 - 102, XP002539225

DOI:   http://dx.doi.org/10.1038/5042
    - SHEKAR, S.C., WU, H., FU, Z., YIP, S.-C., NAGAJYOTHI;, CAHILL, S.M., GIRVIN, M.E., BACKER, J.M., "Mechanism of Constitutive Phosphoinositide 3-Kinase Activation by Oncogenic Mutants of the p85 Regulatory Subunit", J. BIOL. CHEM., (2005), vol. 280, pages 27850 - 27855
    - SILVESTRINI, R., ZAFFARONI, N., ORLANDI, L., ORIANA, S., "In vitro cytotoxic activity of taxol and taxotere on primary cultures and established cell lines of human ovarian cancer", STEM CELLS, (1993), vol. 11, pages 528 - 535
    - STAHL, J.M., CHEUNG, M., SHARMA, A., TRIVEDI, N.R., SHANMUGAM, S., ROBERTSON, G.P., "Loss of PTEN Promotes Tumor Development in Malignant Melanoma", CANCER RES., (2003), vol. 63, pages 2881 - 2890, XP002590380
    - STAMBOLIC, V., SUZUKI, A., DE LA POMPA, J.L., BROTHERS, G.M., MIRTSOS, C., SASAKI, T., RULAND, J., PENNINGER, J.M., SIDEROVSKI, D., "Negative regulation of PKB/Akt-Dependent cell survival by the tumor suppressor PTEN", CELL, (1998), vol. 95, doi:doi:10.1016/S0092-8674(00)81780-8, pages 29 - 39, XP002984475

DOI:   http://dx.doi.org/10.1016/S0092-8674(00)81780-8
    - STAUFFER, F., HOLZER, P., GARCIA-ECHEVERRIA, C., "Blocking the PI3K/PKB pathway in tumor cells", CURR. MED. CHEM.: ANTI-CANCERAGENTS, (2005), vol. 5, doi:doi:10.2174/1568011054866937, pages 449 - 462, XP009112438

DOI:   http://dx.doi.org/10.2174/1568011054866937
    - STECK, P.A., PERSHOUSE, M.A., JASSER, S.A., YUNG, W.K.A., LIN, H., LIGON, A.H., LANGFORD, L.A., BAUMGARD, M.L., HATTIER, T., DAVIS, "Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers", NAT. GENET., (1997), vol. 15, pages 356 - 362
    - STEPHENS, L., WILLIAMS, R., HAWKINS, P., "Phosphoinositide 3-kinases as drug targets in cancer", CURR. OPIN. PHARMACOL., (2005), vol. 5, doi:doi:10.1016/j.coph.2005.03.002, pages 357 - 365, XP004969001

DOI:   http://dx.doi.org/10.1016/j.coph.2005.03.002
    - STILL, W.C., KAHN, M., MITRA, A., "Rapid chromatographic technique for preparative separations with moderate resolution", J. ORG. CHEM., (1978), vol. 43, doi:doi:10.1021/jo00408a041, pages 2923 - 2925, XP000882390

DOI:   http://dx.doi.org/10.1021/jo00408a041
    - STRICKLEY, R.G., "Parenteral formulations of small molecules therapeutics marketed in the United States (1999). Part I", PDA J. PHARM. SCI. TECHNOL., (1999), vol. 53, pages 324 - 349
    - SU, J.D., MAYO, L.D., DONNER, D.B., DURDEN, D.L., "PTEN and Phosphatidylinositol 3'-Kinase Inhibitors Up-Regulate p53 and Block Tumor-induced Angiogenesis: Evidence for an Effect on the Tumor and Endothelial Compartment", CANCER RES., (2003), vol. 63, pages 3585 - 3592, XP008083881
    - TANAKA, M., GROSSMAN, H.B., "In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin", GENE THERAP., (2003), vol. 10, pages 1636 - 1642
    - TANG, E.D., NUNEZ, G., BARR, F.G., GUAN, K.-L., "Negative regulation of the forkhead transcription factor FKHR by Akt", J. BIOL. CHEM., (1999), vol. 274, doi:doi:10.1074/jbc.274.24.16741, pages 16741 - 16746, XP002983897

DOI:   http://dx.doi.org/10.1074/jbc.274.24.16741
    - TAYLOR, V., WONG, M., BRANDTS, C., REILLY, L., DEAN, N.M., COWSERT, L.M., MOODIE, S., STOKOE, D., "5' Phospholipid phosphatase SHIP-2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells", MOL. CELL. BIOL., (2000), vol. 20, pages 6860 - 6871
    - TOKER, A., "Phosphoinositides and signal transduction", CELL MOL. LIFE SCI., (2002), vol. 59, pages 761 - 779
    - TRAER, C.J., FOSTER, F.M., ABRAHAM, S.M., FRY, M.J., "Are class II phosphoinositide 3-kinases potential targets for anticancer therapies?", BULL. CANCER (PARIS, (2006), vol. 93, pages E53 - 58, XP002697164
    - VANHAESEBROECK, B., LEEVERS, S.J., AHMADI, K., TIMMS, J., KATSO, R., DRISCOLL, P.C., WOSCHOLSKI, R., PARKER, P.J., WATERFIELD, M.D, "Synthesis and function of 3-phosphorylated inositol lipids", ANN. REV. BIOCHEM., (2001), vol. 70, pages 535 - 602
    - VANHAESEBROECK, B., WATERFIELD, M.D., "Signaling by Distinct Classes of Phosphoinositide 3-Kinases", EXP. CELL RES., (1999), vol. 253, pages 239 - 254
    - VIVANCO, I., SAWYERS, C.L., "The phosphatidylinositol 3- Kinase-AKT pathway in human cancer", NAT. REV. CANCER, (2002), vol. 2, doi:doi:10.1038/nrc839, pages 489 - 501, XP009035869

DOI:   http://dx.doi.org/10.1038/nrc839
    - VOGT, P.K., GYMNOPOULOS, M., HART, J.R., "PI 3-kinase and cancer: changing accents", CURR. OPIN. GENET. DEV., (2009), vol. 19, doi:doi:10.1016/j.gde.2008.11.011, pages 12 - 17, XP025994212

DOI:   http://dx.doi.org/10.1016/j.gde.2008.11.011
    - WANG, Y., HELLAND, A., HOLM, R., KRISTENSEN GUNNAR, B., BORRESEN-DALE, A.-L., "PIK3CA mutations in advanced ovarian carcinomas", HUMAN MUTATION, (2005), vol. 25, page 322
    - WEE, S., LENGAUER, C., WIEDERSCHAIN, D., "Class IA phosphoinositide 3-kinase isoforms and human tumorigenesis: implications for cancer drug discovery and development", CURR. OPIN. ONCOL., (2008), vol. 20, doi:doi:10.1097/CCO.0b013e3282f3111e, pages 77 - 82, XP009172155

DOI:   http://dx.doi.org/10.1097/CCO.0b013e3282f3111e
    - WEST, K.A., CASTILLO, S.S., DENNIS, P.A., "Activation of the PI3K/Akt pathway and chemotherapeutic resistance", DRUG RESIST. UPDATES, (2002), vol. 5, doi:doi:10.1016/S1368-7646(02)00120-6, pages 234 - 248, XP002964818

DOI:   http://dx.doi.org/10.1016/S1368-7646(02)00120-6
    - WHYTE, D.B., HOLBECK, S.L., "Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines", BIOCHEM BIOPHYS. RES. COMMUN., (2006), vol. 340, pages 469 - 475
    - WILKER, E., LU, J., RHO, 0., CARBAJAL, S., BELTRAN, L., DIGIOVANNI, J., "Role of P13K/Akt signaling in insulin-like growth factor-1 (IGF-1) skin tumor promotion", MOL. CARCINOG., (2005), vol. 44, doi:doi:10.1002/mc.20132, pages 137 - 145, XP055231296

DOI:   http://dx.doi.org/10.1002/mc.20132
    - WORKMAN, P., "Inhibiting the phosphoinositide 3- kinase pathway for cancer treatment", BIOCHEM. SOC. TRANS., (2004), vol. 32, pages 393 - 396
    - WU, G., XING, M., MAMBO, E., HUANG, X., LIU, J., GUO, Z., CHATTERJEE, A., GOLDENBERG, D., GOLLIN, S.M., SUKUMAR, S., "Somatic mutation and gain of copy number of PIK3CA in human breast cancer", BREAST CANCER RES., (2005), vol. 7, doi:doi:10.1186/bcr1262, pages R609 - R616, XP021011863

DOI:   http://dx.doi.org/10.1186/bcr1262
    - YAP, D.B., HSIEH, J.K., LU, X., "Mdm2 inhibits the apoptotic function of p53 mainly by targeting it for degradation", J. BIOL. CHEM., (2000), vol. 275, pages 37296 - 37302
    - YUAN, T.L., CANTLEY, L.C., "P13K pathway alterations in cancer: variations on a theme", ONCOGENE, (2008), vol. 27, doi:doi:10.1038/onc.2008.245, pages 5497 - 5510, XP055082753

DOI:   http://dx.doi.org/10.1038/onc.2008.245
    - YUAN, Z.-Q., FELDMAN, R.I., SUSSMAN, G.E., COPPOLA, D., NICOSIA, S.V., CHENG, J.Q., "AKT2 Inhibition of Cisplatin-induced JNK/p38 and Bax Activation by Phosphorylation of ASK1: Implication of AKT2 in Chemoresistance", J. BIOL. CHEM., (2003), vol. 278, pages 23432 - 23440
    - ZHAO, H., DUPONT, J., YAKAR, S., KARAS, M., LEROITH, D., "PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells", ONCOGENE, (2004), vol. 23, doi:doi:10.1038/sj.onc.1207162, pages 786 - 794, XP008083876

DOI:   http://dx.doi.org/10.1038/sj.onc.1207162
    - ZHAO, J.J., CHENG, H., JIA, S.;, WANG, L., GJOERUP, O.V., MIKAMI, A., ROBERTS, T.M., "The p110a isoform of P13K is essential for proper growth factor signaling and oncogenic transformation", PROC. NATL. ACAD. SCI. U.S.A., (2006), vol. 103, doi:doi:10.1073/pnas.0607899103, pages 16296 - 16300, XP002462087

DOI:   http://dx.doi.org/10.1073/pnas.0607899103
    - ZHICHKIN, P., FAIRFAX, D.J., EISENBEIS, S.A., "A general procedure for the synthesis of 2-substituted pyrimidine-5-carboxylic esters", SYNTHESIS, (2002), pages 720 - 722
    - ZHOU, B.P., LIAO, Y., XIA, W., SPOHN, B., LEE, M.H., HUNG, M.C., "Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu- overexpressing cells", NAT. CELL BIOL., (2001), vol. 3, pages 245 - 252
L'OEB décline toute responsabilité quant à l’exactitude des données émanant d'administrations tierces. Il ne garantit notamment pas l'exhaustivité, l'actualité ou la pertinence à des fins spécifiques de ces données.